{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-021233","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.733834+00:00","generated_at":"2026-06-04T23:58:08.715172+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MoonLake reports 24-week PsA data with ~60% ACR50; plans Phase 3 HS trials in Q2 2024","bullets":["ARGO trial: ~60% ACR50 at week 24; ~40% ACR70; >80% PASI90; ~60% PASI100; low discontinuation ~5%.","Composite responses: ACR50+PASI100 up to 52%, MDA up to 61%; sonelokimab outperformed adalimumab.","Regulatory feedback from FDA/EMA supports Phase 3 HS program (VELA) enrolling 800 patients; top-line data expected mid-2025.","US real-world data: 2M diagnosed HS patients; market opportunity >$10B by 2035; low biologic penetration ~3%.","Four additional clinical trials imminent in new indications (palmo-plantar pustulosis, juvenile HS, seronegative SpA)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-021233","json":"https://secwatch.observer/filing/0001213900-24-021233.json","markdown":"https://secwatch.observer/filing/0001213900-24-021233.md","text":"https://secwatch.observer/filing/0001213900-24-021233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000121390024021233/0001213900-24-021233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000121390024021233/ea0201498-8k_moonlake.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:58:08.715172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}